Is the CSL share price still a buy?

The CSL Limited (ASX: CSL) share price soared to an all-time high of $242.10 this September after stellar full-year results. But has the biotech behemoth reached a share price ceiling?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price soared to an all-time high of $242.10 this month after stellar full-year results, but has the biotech behemoth reached a share price ceiling?

Background on CSL

CSL has outperformed the S&P/ASX 200 (INDEXASX: XJO) by 4.6% year-to-date, gaining 24.6%. Looking at its performance across the past 5 years, the CSL share price has gained 165% since the start of 2015.

The CSL market capitalisation now sits at a staggering $105 billion, with net assets of US$5,251 million as of full-year 2019. Its market capitalisation is nearly eight times the size of its nearest ASX biotech and healthcare rivals – Sonic Healthcare Limited (ASX: SHL), Ramsay Health Limited (ASX: RHC) and Cochlear Limited (ASX: COH).

Not surprisingly, Ernst & Young found that CSL represented 92% of all Australian biotech industry revenues in 2015.

CSL's full-year 2019 earnings results

CSL's total revenue was US$8,757 million, up 11% at constant currency and net profit after tax (NPAT) of US$1,919 million, up a hefty 17%.

The results were highly positive, meeting CSL's already sizeable guidance expectations.

Since FY15, CSL's NPAT has grown by 46.1% and its total operating revenue has risen by 56%. 

Overweight or overrated? 

CSL's price-to-earnings (P/E) ratio is a somewhat high 38, which is higher than the likes of Sonic (22.6) and Ramsay (24.6). Yet CSL's P/E is lower than sector competitors ResMed Inc (ASX: RMD) (48.1) and Cochlear (44.1).

Not only that, CSL's FY19 earnings-per-share (EPS) grew 16% at constant currency, whereas ResMed's adjusted EPS only grew 9% over the last five years. It seems investors think the P/E premium is justified for a market leader with a strong balance sheet and earnings growth.

Can CSL's growth continue? 

Strong product sales

CSL's Behring arm accounts for 85% of its revenue by specialising in therapies for rare and serious diseases. This expertise differentiates CSL's main products and acts as a moat against rivals.

Indeed, its core products Privigen, Hizentra, and Albumin went up 23%, 22%, and 15%, respectively, in FY19. Not only that, CSL's transformational therapies for hereditary angioedema and haemophilia B saw staggering growth of 61% and 40%, respectively.

Additionally, CSL's recently acquired Seqirus subsidiary reported last October that its influenza vaccine was 36% more effective than standard vaccines in preventing influenza-related illnesses during the 2017/18 influenza season.

Further positive developments include CSL wholly acquiring a Chinese pharmaceutical company that has a license to buy and sell inventory in China's domestic market. This is great news for CSL, as China's growth pastures are tough to access – just ask Bellamy's Australia Ltd (ASX: BAL). 

Boom in biotech sector and rising healthcare spending

The World Health Organization reported that healthcare expenditure accounted for 10% of global GDP and that global healthcare spending is rising 5% annually. 

In line with this, reports by the likes of McKell Institute suggest that Australia's biotech sector is expected to grow at an annual rate of 4.4% at least until 2021.

However, CSL is an international enterprise, and the same report found that the global biotech sector is growing at 10% a year. 

Given CSL has invested US$3.3 billion in R&D over the last five years and has already registered 24 biotech products this year, it has demonstrated that it is well-placed to meet rising healthcare demand. 

Forecasts and estimates

Looking forward, CSL's CEO Paul Perreault reported that "CSL's net profit after tax for FY20 is anticipated to be in the range of approximately $2,050 million to $2,110 million at constant currency, representing growth over FY19 of approximately 7–10%."

Of 13 analysts profiled by the Wall Street Journal, 7 deemed CSL a buy and the remaining six a hold. No analyst reported CSL a sell. Blackrock Inc and Vanguard Group are both substantial CSL shareholders with 5% voting rights each.

Foolish takeaway

CSL is largely insulated from trade war shocks and economic cycles, making it an appealing alternative to stocks that may toss in the headwinds of US–China trade war and a gloomy economic outlook. Demand for life-saving biotechnology is more inelastic than demand for discretionary products. 

In the short-to-medium term, all signs suggest healthcare spending will continue to rise, and medical and biotechnological innovation will only spur that growth.

As a global leader in biotech, CSL has many products in the pipeline and spends heavily on R&D, diluting potential over-reliance on any one product and negating competition threats. 

It seems CSL still has enough runway left for share price lift-off.

Kiryll Prakapenka has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. and CSL Ltd. The Motley Fool Australia has recommended Cochlear Ltd., Ramsay Health Care Limited, ResMed Inc., and Sonic Healthcare Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »